Cryoport’s Q1 2026 Earnings in Focus

Cryoport (CYRX) has just reported its Q1 2026 results with recent quarterly revenue most recently at about US$45.5 million and a basic EPS loss of US$0.21, keeping the spotlight firmly on how efficiently the company is converting top line into earnings. The company has seen revenue move from US$41.5 million in Q4 2024 to US$45.5 million in Q4 2025, while quarterly basic EPS has ranged from a loss of US$0.39 to a loss of US$0.17 over that period. This gives investors a clear view of how margins are tracking as the business scales. With trailing 12 month revenue at US$176.2 million against a net loss of US$42.0 million, the latest quarter keeps the focus on whether Cryoport can keep tightening its margins from here.

See our full analysis for Cryoport.

With the headline numbers on the table, the next step is to set these results against the most widely held narratives about Cryoport to see which stories hold up and which ones the latest margin trends start to challenge.

Quarterly losses still over US$10 million

• Net income excluding extra items was a loss of US$10.5 million in Q4 2025, compared with losses between about US$8.7 million and US$11.7 million over the prior three quarters, and a US$19.2 million loss in Q4 2024.
• Consensus narrative points to improving efficiency and a path toward stronger margins over time. These figures, however, show the business is still some distance from breakeven, with:
  • Trailing 12 month net income excluding extra items at a loss of US$42.0 million, even as revenue on the same basis is US$176.2 million.
  • Losses shrinking at about 16.9% per year over five years, which supports the idea of progress but also highlights that the company remains firmly loss making for now.

Revenue growth at 9.5% a year

• On a trailing 12 month basis, revenue growth is 9.5% per year, with quarterly revenue in 2025 ranging from US$41.0 million to about US$45.5 million and trailing 12 month revenue most recently at US$176.2 million.
• Bulls argue that backing roughly 70% of cell and gene clinical trials and adding services like IntegriCell could support long term revenue expansion. The current numbers partly line up with that story, because:
  • Revenue has held in the low US$40 million to mid US$40 million range through 2025, which is consistent with a business that is still growing rather than shrinking.
  • At the same time, the 9.5% annual growth rate is below the 11.2% broader US market rate cited, which tests the bullish claim that Cryoport is on a much faster growth path than the wider market.

Bulls point to Cryoport's role in cell and gene therapy logistics and new services as reasons the current 9.5% revenue growth and improving loss trend could be the start of a longer runway, while the actual margin and growth numbers keep expectations grounded in what is happening today.🐂 Cryoport Bull Case

Valuation premium with no near term profit

• The stock trades at US$12.19, above the DCF fair value estimate of about US$10.99, while the P/S of 3.5x is below peer averages at 4.2x but slightly above the US Life Sciences industry at 3.4x.
• Bears highlight that forecasts in the supplied data do not show profitability in the next three years, and the current valuation mix gives them some support, because:
  • The share price sits above the DCF fair value while the company is unprofitable, with trailing 12 month EPS at a loss of US$0.84 and net income excluding extra items at a loss of US$42.0 million.
  • Even with losses narrowing over five years, the expectation of continued losses and recent insider selling mentioned in the analysis make it easier for cautious investors to question paying more than the modeled DCF fair value.

For a cautious investor, the combination of ongoing losses, forecasts that do not show near term profitability, and a share price above the DCF fair value keeps the focus on how much optimism is already reflected in the current valuation.🐻 Cryoport Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Cryoport on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

With mixed signals on growth, margins, and valuation through the rest of this article, it makes sense to move quickly and weigh the trade off between Cryoport’s challenges and potential by checking the 1 key reward and 2 important warning signs.

See What Else Is Out There

Cryoport is still posting quarterly losses of over US$10 million, with no near term profitability in the supplied forecasts and a share price above DCF fair value.

If you want stocks where the price better reflects current earnings strength, use the 51 high quality undervalued stocks today and compare opportunities side by side.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.